Matches in SemOpenAlex for { <https://semopenalex.org/work/W2134264112> ?p ?o ?g. }
Showing items 1 to 81 of
81
with 100 items per page.
- W2134264112 endingPage "324" @default.
- W2134264112 startingPage "321" @default.
- W2134264112 abstract "To investigate the efficacy, effectiveness and safety of etanercept, a soluble tumour necrosis factor-alpha receptor, in a prospective observational cohort of patients with refractory psoriatic arthritis and polyarticular involvement.Twenty patients with psoriatic arthritis refractory to conventional anti-rheumatic drugs were treated with etanercept 25 mg subcutaneously twice a week for 26 weeks. Efficacy and safety were recorded at weeks 2, 6, 10, 16, 20 and 26. Effectiveness, defined as clinical remission, reduction of 50% in clinical parameters and concomitant NSAID use, was evaluated at 26 weeks.Etanercept therapy was efficacious in this cohort as 85% of the patients met the Psoriatic Arthritis Response Criterion at week 26. Effectiveness of etanercept for the individual patient was demonstrated, since at least 50% of the patients had a 90 and 85% improvement in swollen and tender joint count, respectively, and a 71% improvement in the Health Assessment Questionnaire at week 26. Four patients showed complete remission and NSAIDs were stopped in 10/15 patients. The most common adverse events were upper respiratory tract infections. Interestingly, in two patients psoriasis worsened during the study, unrelated to the course of arthritis. The administration of etanercept was interrupted in three patients for adverse events: one septic bursitis, one myocardial infarction and one tooth abscess. After resolution of the adverse events, etanercept was successfully reintroduced.Etanercept in monotherapy is efficacious, effective and safe in the majority of patients with refractory psoriatic arthritis." @default.
- W2134264112 created "2016-06-24" @default.
- W2134264112 creator A5018912842 @default.
- W2134264112 creator A5087471106 @default.
- W2134264112 date "2005-10-18" @default.
- W2134264112 modified "2023-10-01" @default.
- W2134264112 title "Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study" @default.
- W2134264112 cites W1968958817 @default.
- W2134264112 cites W1976217778 @default.
- W2134264112 cites W2003266662 @default.
- W2134264112 cites W2038089071 @default.
- W2134264112 cites W2056516039 @default.
- W2134264112 cites W2078610240 @default.
- W2134264112 cites W2094124191 @default.
- W2134264112 cites W2108278277 @default.
- W2134264112 cites W2140235660 @default.
- W2134264112 cites W2149168537 @default.
- W2134264112 cites W2168698481 @default.
- W2134264112 doi "https://doi.org/10.1093/rheumatology/kei153" @default.
- W2134264112 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16234275" @default.
- W2134264112 hasPublicationYear "2005" @default.
- W2134264112 type Work @default.
- W2134264112 sameAs 2134264112 @default.
- W2134264112 citedByCount "27" @default.
- W2134264112 countsByYear W21342641122012 @default.
- W2134264112 countsByYear W21342641122013 @default.
- W2134264112 countsByYear W21342641122014 @default.
- W2134264112 crossrefType "journal-article" @default.
- W2134264112 hasAuthorship W2134264112A5018912842 @default.
- W2134264112 hasAuthorship W2134264112A5087471106 @default.
- W2134264112 hasBestOaLocation W21342641121 @default.
- W2134264112 hasConcept C121332964 @default.
- W2134264112 hasConcept C126322002 @default.
- W2134264112 hasConcept C141071460 @default.
- W2134264112 hasConcept C142424586 @default.
- W2134264112 hasConcept C16005928 @default.
- W2134264112 hasConcept C197934379 @default.
- W2134264112 hasConcept C2776260265 @default.
- W2134264112 hasConcept C2777077863 @default.
- W2134264112 hasConcept C2777226972 @default.
- W2134264112 hasConcept C2777575956 @default.
- W2134264112 hasConcept C2779384505 @default.
- W2134264112 hasConcept C2780564577 @default.
- W2134264112 hasConcept C71924100 @default.
- W2134264112 hasConcept C87355193 @default.
- W2134264112 hasConceptScore W2134264112C121332964 @default.
- W2134264112 hasConceptScore W2134264112C126322002 @default.
- W2134264112 hasConceptScore W2134264112C141071460 @default.
- W2134264112 hasConceptScore W2134264112C142424586 @default.
- W2134264112 hasConceptScore W2134264112C16005928 @default.
- W2134264112 hasConceptScore W2134264112C197934379 @default.
- W2134264112 hasConceptScore W2134264112C2776260265 @default.
- W2134264112 hasConceptScore W2134264112C2777077863 @default.
- W2134264112 hasConceptScore W2134264112C2777226972 @default.
- W2134264112 hasConceptScore W2134264112C2777575956 @default.
- W2134264112 hasConceptScore W2134264112C2779384505 @default.
- W2134264112 hasConceptScore W2134264112C2780564577 @default.
- W2134264112 hasConceptScore W2134264112C71924100 @default.
- W2134264112 hasConceptScore W2134264112C87355193 @default.
- W2134264112 hasIssue "3" @default.
- W2134264112 hasLocation W21342641121 @default.
- W2134264112 hasLocation W21342641122 @default.
- W2134264112 hasOpenAccess W2134264112 @default.
- W2134264112 hasPrimaryLocation W21342641121 @default.
- W2134264112 hasRelatedWork W184038900 @default.
- W2134264112 hasRelatedWork W1990793367 @default.
- W2134264112 hasRelatedWork W2048626246 @default.
- W2134264112 hasRelatedWork W2066747763 @default.
- W2134264112 hasRelatedWork W2079213394 @default.
- W2134264112 hasRelatedWork W2146304976 @default.
- W2134264112 hasRelatedWork W2151418048 @default.
- W2134264112 hasRelatedWork W2168698481 @default.
- W2134264112 hasRelatedWork W2185641146 @default.
- W2134264112 hasRelatedWork W2436691129 @default.
- W2134264112 hasVolume "45" @default.
- W2134264112 isParatext "false" @default.
- W2134264112 isRetracted "false" @default.
- W2134264112 magId "2134264112" @default.
- W2134264112 workType "article" @default.